Thrivent Financial for Lutherans Sells 20,775 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Thrivent Financial for Lutherans cut its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 44.6% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 25,802 shares of the company's stock after selling 20,775 shares during the period. Thrivent Financial for Lutherans' holdings in Neurocrine Biosciences were worth $2,973,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of NBIX. O Shaughnessy Asset Management LLC raised its holdings in Neurocrine Biosciences by 16.8% in the first quarter. O Shaughnessy Asset Management LLC now owns 3,695 shares of the company's stock worth $510,000 after purchasing an additional 531 shares during the period. Public Employees Retirement System of Ohio raised its holdings in shares of Neurocrine Biosciences by 6.6% during the first quarter. Public Employees Retirement System of Ohio now owns 47,947 shares of the company's stock worth $6,613,000 after acquiring an additional 2,987 shares during the period. Kennedy Capital Management LLC raised its holdings in shares of Neurocrine Biosciences by 55.4% during the first quarter. Kennedy Capital Management LLC now owns 33,236 shares of the company's stock worth $4,584,000 after acquiring an additional 11,850 shares during the period. Redwood Investment Management LLC acquired a new stake in shares of Neurocrine Biosciences during the first quarter worth $642,000. Finally, Motley Fool Asset Management LLC raised its holdings in shares of Neurocrine Biosciences by 10.5% during the first quarter. Motley Fool Asset Management LLC now owns 2,067 shares of the company's stock worth $285,000 after acquiring an additional 197 shares during the period. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Needham & Company LLC restated a "hold" rating on shares of Neurocrine Biosciences in a report on Monday, November 11th. HC Wainwright restated a "buy" rating and set a $190.00 price objective on shares of Neurocrine Biosciences in a report on Friday, November 1st. Oppenheimer raised their target price on shares of Neurocrine Biosciences from $216.00 to $219.00 and gave the company an "outperform" rating in a research report on Friday, August 2nd. Barclays decreased their target price on shares of Neurocrine Biosciences from $180.00 to $160.00 and set an "overweight" rating for the company in a research report on Monday, September 9th. Finally, Royal Bank of Canada decreased their target price on shares of Neurocrine Biosciences from $136.00 to $133.00 and set a "sector perform" rating for the company in a research report on Friday, October 4th. Five equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $163.91.

Neurocrine Biosciences Stock Performance

Shares of NBIX opened at $127.91 on Wednesday. Neurocrine Biosciences, Inc. has a 52 week low of $110.52 and a 52 week high of $157.98. The firm has a market cap of $12.95 billion, a P/E ratio of 34.29 and a beta of 0.35. The firm's 50-day simple moving average is $118.83 and its 200 day simple moving average is $131.74.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.